Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Adolfsson

Showing results (121-130 of 168) with videos related to

Pageof 17
Sort By:
BMC Urology|August 7, 2019
Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?Kerri Beckmann, Netty Kinsella, Henrik Olsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2012
Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based studyVoralak Vichapat, Hans Garmo, Marit Holmqvist, et al.
Scandinavian Journal of Urology|May 13, 2022
Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonistsTiago M Bonde, Marcus Westerberg, Markus Aly, et al.
European Radiology|April 12, 2023
Magnetic resonance imaging of the knee for chronological age estimation-a systematic reviewLil-Sofie Ording Muller, Jan Adolfsson, Lisa Forsberg, et al.
The Lancet. Oncology|April 17, 2010
Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe SwedenMieke Van Hemelrijck, Jan Adolfsson, Hans Garmo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe SwedenMieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al.
Ecancermedicalscience|February 20, 2018
A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitusDanielle Crawley, Florence Chamberlain, Hans Garmo, et al.
BJU International|January 15, 2019
Androgen deprivation therapy for prostate cancer and risk of dementiaDavid Robinson, Hans Garmo, Mieke Van Hemelrijck, et al.
Frontiers in Oncology|November 2, 2020
Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control StudyJonathan Parker, Danielle Crawley, Hans Garmo, et al.
European Urology|July 17, 2017
Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based StudyFrederik Birkebæk Thomsen, Fredrik Sandin, Hans Garmo, et al.
Pageof 17

Showing results (121-130 of 168) with videos related to

Sort By:
Pageof 17
BMC Urology|August 7, 2019
Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?Kerri Beckmann, Netty Kinsella, Henrik Olsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2012
Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based studyVoralak Vichapat, Hans Garmo, Marit Holmqvist, et al.
Scandinavian Journal of Urology|May 13, 2022
Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonistsTiago M Bonde, Marcus Westerberg, Markus Aly, et al.
European Radiology|April 12, 2023
Magnetic resonance imaging of the knee for chronological age estimation-a systematic reviewLil-Sofie Ording Muller, Jan Adolfsson, Lisa Forsberg, et al.
The Lancet. Oncology|April 17, 2010
Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe SwedenMieke Van Hemelrijck, Jan Adolfsson, Hans Garmo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe SwedenMieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al.
Ecancermedicalscience|February 20, 2018
A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitusDanielle Crawley, Florence Chamberlain, Hans Garmo, et al.
BJU International|January 15, 2019
Androgen deprivation therapy for prostate cancer and risk of dementiaDavid Robinson, Hans Garmo, Mieke Van Hemelrijck, et al.
Frontiers in Oncology|November 2, 2020
Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control StudyJonathan Parker, Danielle Crawley, Hans Garmo, et al.
European Urology|July 17, 2017
Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based StudyFrederik Birkebæk Thomsen, Fredrik Sandin, Hans Garmo, et al.
Pageof 17